BIOVIA’s Post

When ADC Therapeutics realized that paper lab notebooks were holding them back, it was time to move to a cloud-based lab management solution. The clinical-stage oncology drug discovery and development company needed a solution to help manage the vast amounts of data and improve opportunities for collaboration and connectivity across ADCTs sites globally. 🌎 We interviewed ADCT scientist, Charlie Britten to find out what impact investing in Labguru's management solution has had on the company in terms of streamlining processes and increasing productivity and collaboration. You can learn more by clicking on the link below to read the full case study.👇 https://bit.ly/3PzNkQi #ELN #Labguru #Labmanagement

Operate freely with our robust offering of ~500 standard cell lines, licensed, well characterized, and annotated for your screening needs. What sets OmniScreen™ apart? ⬇️ ✅Unmatched Selection: Choose from 30+ cancer indications. ✅Versatile Design: Engage in 3D models, drug combination studies, extended incubation & more. ✅Holistic Solution: From composite biomarker analysis to in vivo follow up with our XenoSelect™ panel. ✅Real-time Insights: Access results promptly with our real-time readouts. Unlock a future where your lead therapeutic agents are the next big breakthrough in preclinical drug development! Register by June 13th ➡️https://hubs.la/Q02yF2fP0 #CancerResearch #CellLines #DrugDevelopment

Today marks a big milestone for GAIN Therapeutics, one of our investment company, as they move from preclinical to clinical stage, with the first two subjects dosed in the Phase 1 Trial of GT-02287, their novel GCase-targeting small molecule therapy for GBA1 Parkinsons disease. The single center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose (SAD/MAD) study is designed to evaluate the safety and tolerability of GT-02287 in healthy adults and to identify recommended doses for further clinical development in the setting of GBA1 Parkinson’s disease. In addition, as an exploratory endpoint, this study will look at GCase target engagement and activity in blood, which may provide an early clinical validation of the effect of GT-02287 on GCase. Learn more: https://lnkd.in/ggt5g8S8

🐁 🎙️ Check out Episode 3 of the HuMice Pubcast! Discover how Roche’s use of humanized #mousemodels drove a successful transition from preclinical discovery to a Phase 1 clinical trial. Then we dive into the humanized FcRn model used to assess human PK for calculating a safe starting dose:

We're happy to announce the next chapter of our webinar series on East and Solara R Integration! Part three will focus on simulating time-to-event patient data with alternative distributions. Valeria Mazzanti and Kyle Wathen will cover the following use cases anchored in an oncology study design example: ✔️Selecting alternative distributions for response generation ✔️Applying a Weibull distribution to simulate patient data, allowing for changing hazards over time ✔️Changing the analysis type with Bayesian method variations Register here for the webinar 👉 https://bit.ly/4b7yEzX #biotech #pharma #pharmaceuticalindustry #OncologyTrials

May 8th we are hosting a webinar on extending our EAST and Solara platforms with R. This hybrid approach allows our clients the flexibility of custom R code with the power of commercial software, allowing you to focus on strategy while designing your clinical trial. Valeria Mazzanti and Kyle Wathen will cover the following use cases anchored in an oncology study design example: ✔️Selecting alternative distributions for response generation ✔️Applying a Weibull distribution to simulate patient data, allowing for changing hazards over time ✔️Changing the analysis type with Bayesian method variations Register here for the webinar 👉 https://bit.ly/4b7yEzX

From lab to clinic: Veristat's roadmap to success! See how our comprehensive planning empowered a biotech company's first Phase I trial. 🔑 Key takeaway - planning is the foundation of success. Download the case study to learn more 📩 https://bit.ly/4a6LRJR #ClinicalDevelopment #cancerantibody #phaseitrial